
|Videos|August 4, 2017
Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCC
Author(s)Brian I. Rini, MD
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the efficacy of pembrolizumab (Keytruda) and axitinib (Inlyta) combined in patients with renal cell carcinoma (RCC).
Advertisement
Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the efficacy of pembrolizumab (Keytruda) and axitinib (Inlyta) combined in patients with renal cell carcinoma (RCC).
There was a trial of 52 previously untreated patients with RCC who received axitinib and prembrolizumab. The response rate with this combination was 71%, whereas single-agent axitinib typically sees response rates in the 30% to 40% range, making these results the best that has been seen in RCC, states Rini.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5



































